AMCX is in an unusual position heading into its June 16 earnings call: the stock has recovered sharply but the bears have not flinched.
Short sellers have dug in rather than retreated during the rebound. Short interest has climbed to 18.1% of the free float — up from roughly 16.6% at the end of March and now sitting near a six-week high. Week-on-week, shorts added another 4.2% to their position even as the stock gained 2.7% to close at $8.80. The pattern is straightforward: buyers pushed the price up 16% over the past month, but the short book grew at almost the same time, keeping the structural tension in place. ORTEX's short score of 72.4 — in roughly the 5th percentile of the universe for bearishness — reflects exactly that tension. Days to cover now stand at 11 days, which means any sharp squeeze would take meaningful time to work through.
Borrow conditions, however, offer little urgency for either side. The lending market is not particularly tight: availability has eased over the past month, and the cost to borrow has actually fallen around 20% week-on-week to just 0.38%. That is a very cheap rate to maintain a short position, which helps explain why bears are not rushing to cover despite the price move. Share availability data from earlier in April — when utilization briefly touched its 52-week high — has since loosened, removing one potential catalyst for a forced unwind. Options positioning tells the same relaxed story. The put/call ratio of 0.42 is essentially flat against its 20-day average of 0.42, with a z-score barely above zero. There is no sign of unusual hedging or directional urgency in the options market.
The Street has not warmed to AMCX in any meaningful way. The analyst consensus leans bearish: Morgan Stanley and JPMorgan both carry Underweight or Sell ratings, and the mean price target of $7.50 is actually below the current price of $8.80 — implying roughly 15% downside from analysts who cover the name. That's an unusual setup for a stock that has just posted a strong one-month run. The most recent analyst action worth noting was Wells Fargo's February 2026 target lift to $10 — the lone voice suggesting upside — though the rating stayed at Equal-Weight. EV/EBITDA of 5.8x is undemanding, and a PE near 5x looks cheap in isolation. But EPS momentum tells the harder story: the 30-day EPS momentum factor scores in the 28th percentile, and the 90-day rank is even weaker at the 22nd. Forward earnings revisions are moving the wrong way.
Ownership structure adds one notable layer to the picture. The Dolan family trust holds 26.6% of shares — a controlling presence that limits the freely traded float. BlackRock added roughly 197,000 shares through April, while American Century added 269,000, both modest but directionally constructive. Marshall Wace trimmed by 226,000 shares late last year, suggesting some hedge fund distribution on the other side. Insider activity was confined to routine equity awards in March, with the Chief Accounting Officer selling small lots — nothing that changes the read on management conviction.
Peer broadcasters are mostly weaker this week. GTN fell more than 23% on the week and SSP dropped nearly 9%, making AMCX's flat-to-up performance notable within the group. Whether that relative resilience reflects genuine differentiation or simply that AMCX already trades at a distressed multiple is the question the June 16 earnings call will clarify.
See the live data behind this article on ORTEX.
Open AMCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
